CA1203167A - Medicament pour le traitement des maladies neoplasiques - Google Patents
Medicament pour le traitement des maladies neoplasiquesInfo
- Publication number
- CA1203167A CA1203167A CA000430434A CA430434A CA1203167A CA 1203167 A CA1203167 A CA 1203167A CA 000430434 A CA000430434 A CA 000430434A CA 430434 A CA430434 A CA 430434A CA 1203167 A CA1203167 A CA 1203167A
- Authority
- CA
- Canada
- Prior art keywords
- treatment
- solution
- herba
- ratio
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 229940079593 drug Drugs 0.000 title claims abstract description 11
- 201000010099 disease Diseases 0.000 title claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 7
- 230000001613 neoplastic effect Effects 0.000 title 1
- 239000002775 capsule Substances 0.000 claims abstract description 18
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229940098465 tincture Drugs 0.000 claims abstract description 10
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 6
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims abstract description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229910052782 aluminium Inorganic materials 0.000 claims abstract description 5
- 239000001164 aluminium sulphate Substances 0.000 claims abstract description 5
- 235000011128 aluminium sulphate Nutrition 0.000 claims abstract description 5
- 229960000907 methylthioninium chloride Drugs 0.000 claims abstract description 5
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims abstract description 5
- 229910052939 potassium sulfate Inorganic materials 0.000 claims abstract description 5
- 239000001120 potassium sulphate Substances 0.000 claims abstract description 5
- 235000011151 potassium sulphates Nutrition 0.000 claims abstract description 5
- 229910002007 uranyl nitrate Inorganic materials 0.000 claims abstract description 5
- 241000693827 Helleborus niger Species 0.000 claims abstract description 4
- 240000004658 Medicago sativa Species 0.000 claims abstract description 4
- 235000010624 Medicago sativa Nutrition 0.000 claims abstract description 4
- 241000581692 Potentilla reptans Species 0.000 claims abstract description 4
- 241000196324 Embryophyta Species 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 3
- 241000534456 Arenaria <Aves> Species 0.000 claims description 2
- 235000012745 brilliant blue FCF Nutrition 0.000 claims 1
- 238000001802 infusion Methods 0.000 abstract description 10
- 230000003387 muscular Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 4
- 235000021152 breakfast Nutrition 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 229960004337 hydroquinone Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002803 maceration Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- LPJXPACOXRZCCP-VIFPVBQESA-N (2s)-2-benzamidopentanedioic acid Chemical class OC(=O)CC[C@@H](C(O)=O)NC(=O)C1=CC=CC=C1 LPJXPACOXRZCCP-VIFPVBQESA-N 0.000 description 1
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003295 alanine group Chemical class N[C@@H](C)C(=O)* 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 235000011126 aluminium potassium sulphate Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 230000003098 cholesteric effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- -1 potash ion Chemical class 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 235000011127 sodium aluminium sulphate Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/50—Fumariaceae (Fumitory family), e.g. bleeding heart
- A61K36/505—Corydalis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RO107893 | 1982-06-16 | ||
| RO82107893A RO81783A3 (fr) | 1982-06-16 | 1982-06-16 | Medicament pour le traitement de la maladie neoplastique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1203167A true CA1203167A (fr) | 1986-04-15 |
Family
ID=20111710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000430434A Expired CA1203167A (fr) | 1982-06-16 | 1983-06-15 | Medicament pour le traitement des maladies neoplasiques |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0111529B1 (fr) |
| CA (1) | CA1203167A (fr) |
| DD (1) | DD210843A5 (fr) |
| DE (1) | DE3366025D1 (fr) |
| IL (1) | IL68896A0 (fr) |
| IT (1) | IT1161934B (fr) |
| RO (1) | RO81783A3 (fr) |
| WO (1) | WO1984000005A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3015481A1 (fr) * | 2013-12-20 | 2015-06-26 | France Etat | Utilisation de composes de diaminophenothiazinium en tant qu'agents de prevention, reduction ou suppression d'une radiotoxicite |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2244468A1 (en) * | 1973-07-31 | 1975-04-18 | Passwater Richard | Anticarcinogenic food supplements - contg antioxidants and S-contg amino acids |
-
1982
- 1982-06-16 RO RO82107893A patent/RO81783A3/fr unknown
-
1983
- 1983-05-26 DE DE8383901948T patent/DE3366025D1/de not_active Expired
- 1983-05-26 EP EP83901948A patent/EP0111529B1/en not_active Expired
- 1983-05-26 WO PCT/RO1983/000001 patent/WO1984000005A1/fr not_active Ceased
- 1983-06-06 IL IL68896A patent/IL68896A0/xx unknown
- 1983-06-14 DD DD83252009A patent/DD210843A5/de unknown
- 1983-06-14 IT IT21614/83A patent/IT1161934B/it active
- 1983-06-15 CA CA000430434A patent/CA1203167A/fr not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3015481A1 (fr) * | 2013-12-20 | 2015-06-26 | France Etat | Utilisation de composes de diaminophenothiazinium en tant qu'agents de prevention, reduction ou suppression d'une radiotoxicite |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1984000005A1 (fr) | 1984-01-05 |
| IT8321614A0 (it) | 1983-06-14 |
| DD210843A5 (de) | 1984-06-27 |
| DE3366025D1 (en) | 1986-10-16 |
| EP0111529B1 (en) | 1986-09-10 |
| RO81783A3 (fr) | 1984-07-17 |
| IL68896A0 (en) | 1983-10-31 |
| IT1161934B (it) | 1987-03-18 |
| RO81783B1 (ro) | 1984-03-08 |
| EP0111529A1 (fr) | 1984-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6030622A (en) | Herbal extract composition and method with immune-boosting capability | |
| Nishino et al. | Antitumor-promoting activity of garlic extracts | |
| US4767626A (en) | Remedy for anemia and arthritis | |
| US3920816A (en) | Composition for treating respiratory diseases | |
| US4839172A (en) | Composition of accelerating recovery of function of hematopoietic organs | |
| DeLuca et al. | Metabolism of tritiated vitamin D3 in familial vitamin D-resistant rickets with hypophosphatemia | |
| CA1203167A (fr) | Medicament pour le traitement des maladies neoplasiques | |
| György | Investigations on the vitamin B2 complex: The inactivation of lactoflavin and vitamin B6 by visible light | |
| RU2147239C1 (ru) | Общеукрепляющее неспецифическое иммуномодулирующее средство | |
| CN1072183A (zh) | 提取蟾蜍灵的方法及其蟾蜍灵和有关衍生物的用途 | |
| DE69900466T2 (de) | Orale zusammensetzungen mit niedrigdosierten zytotoxischen proteinen | |
| DE10340845A1 (de) | Pharmazeutisches Kombinationspräparat, enthaltend Glycyrrhizinsäure, Zink und eine Verbindung, die eine Thiolgruppe oder eine zu dieser metabolisierbare Gruppe enthält | |
| RU2408383C1 (ru) | Композиция с противоопухолевой и адаптогенной активностью (варианты) и лекарственный препарат на ее основе (варианты) | |
| Morcos et al. | Effect of vitamin C and carotene on the absorption of calcium from the intestine | |
| CN109223739B (zh) | 一种组合物及其制备方法和应用 | |
| RU2128053C1 (ru) | Средство для лечения бронхиальной астмы (варианты) | |
| Pharmaceutical Society of Great Britain | British pharmaceutical codex | |
| CN103432541A (zh) | 一种蘘荷花苞提取物的降血脂新用途 | |
| SU1168253A1 (ru) | Способ лечени хронических неспецифических заболеваний легких | |
| RU2120292C1 (ru) | Способ лечения мозговых сосудистых кризов | |
| Daniels | Hospital Formulary: And Compendium of Useful Information | |
| Hallberg | Physicians' Manual of the Pharmacopeia and the National Formulary: An Epitome of All the Articles Contained in the USP (eighth Revision) and the National Formulary | |
| RU2107503C1 (ru) | Средство для обезболивания | |
| Hatcher et al. | Epitome of the Pharmacopeia of the United States and the National Formulary: With Comments | |
| Bethea | Practical Materia Medica and Prescription Writing... |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |